D.A. Davidson & Co. Immuno Gen, Inc. Transaction History

D.A. Davidson & Co.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 13, 2019	SELL	$1.8 - $3.3 $142,930 - $262,039	-79,406 Closed	0 $0
Q1 2019 May 13, 2019	SELL	$2.41 - $5.91 $930 - $2,281	-386 Reduced 0.48%	79,406 $215,000
Q4 2018 Jan 29, 2019	SELL	$3.94 - $9.7 $10,437 - $25,695	-2,649 Reduced 3.21%	79,792 $383,000
Q3 2018 Nov 13, 2018	SELL	$8.6 - $11.26 $32,611 - $42,697	-3,792 Reduced 4.4%	82,441 $781,000
Q2 2018 Aug 02, 2018	SELL	$9.52 - $12.15 $30,435 - $38,843	-3,197 Reduced 3.57%	86,233 $839,000
Q1 2018 May 04, 2018	SELL	$6.7 - $12.95 $26,257 - $50,751	-3,919 Reduced 4.2%	89,430 $941,000
Q4 2017 Feb 08, 2018	SELL	$5.07 - $7.92 $6,165 - $9,630	-1,216 Reduced 1.29%	93,349 $598,000
Q3 2017 Nov 08, 2017	BUY	$5.4 - $8.47 $1,155 - $1,812	214 Added 0.23%	94,565 $723,000
Q2 2017 Aug 11, 2017	BUY	N/A	94,351	94,351 $0

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

Stay updated on D.A. Davidson & Co. with notifications on news.